title: Saturable active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier leads to nonlinear distribution of elacridar to the central nervous system.
abstract: The study objective was to investigate factors that affect the central nervous system (CNS) distribution of elacridar. Elacridar inhibits transport mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) and has been used to study the influence of transporters on brain distribution of chemotherapeutics. Adequate distribution of elacridar across the blood-brain barrier (BBB) and into the brain parenchyma is necessary to target tumor cells in the brain that overexpress transporters and reside behind an intact BBB. We examined the role of P-gp and Bcrp on brain penetration of elacridar using Friend leukemia virus strain B wild-type, Mdr1a/b(-/-), Bcrp1(-/-), and Mdr1a/b(-/-)Bcrp1(-/-) mice. Initially, the mice were administered 2.5 mg/kg of elacridar intravenously, and the plasma and brain concentrations were determined. The brain-to-plasma partition coefficient of elacridar in the wild-type mice was 0.82, as compared with 3.5 in Mdr1a/b(-/-) mice, 6.6 in Bcrp1(-/-) mice, and 15 in Mdr1a/b(-/-)Bcrp1(-/-) mice, indicating that both P-gp and Bcrp limit the brain distribution of elacridar. The four genotypes were then administered increasing doses of elacridar, and the CNS distribution of elacridar was determined. The observed and model predicted maximum brain-to-plasma ratios (Emax) at the highest dose were not significantly different in all genotypes. However, the ED50 was lower for Mdr1a/b(-/-) mice compared with Bcrp1(-/-) mice. These findings correlate with the relative expression of P-gp and Bcrp at the BBB in these mice and demonstrate the quantitative enhancement in elacridar CNS distribution as a function of its dose. Overall, this study provides useful concepts for future applications of elacridar as an adjuvant therapy to improve targeting of chemotherapeutic agents to tumor cells in the brain parenchyma.
authors: Department of Pharmaceutics, Brain Barriers Research Center, University of Minnesota, Minneapolis, Minnesota 55455, USA.
authors: Ramola
authors: R
authors: Sane
authors: Sagar
authors: S
authors: Agarwal
authors: Rajendar K
authors: RK
authors: Mittapalli
authors: William F
authors: WF
authors: Elmquist
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics / Q000378:metabolism; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism*; D000166:Acridines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects* / Q000378:metabolism; D018929:Cell Culture Techniques; D002490:Central Nervous System / Q000187:drug effects / Q000378:metabolism; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007275:Injections, Intravenous; D061985:Madin Darby Canine Kidney Cells; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D017711:Nonlinear Dynamics; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D014018:Tissue Distribution; D000097202:ATP-Binding Cassette Sub-Family B Member 4
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000166:Acridines; D044005:Tetrahydroisoquinolines; D000097202:ATP-Binding Cassette Sub-Family B Member 4; C513055:ABCB1 protein, human; C501412:Abcg2 protein, mouse; C095122:multidrug resistance protein 3; C083501:Elacridar
references: Cancer Res. 1993 Oct 1;53(19):4595-602
references: 8402633
references: Mol Cancer Ther. 2012 Oct;11(10):2183-92
references: 22891038
references: J Pharmacol Exp Ther. 2012 May;341(2):386-95
references: 22323823
references: Clin Cancer Res. 2007 Nov 1;13(21):6440-9
references: 17975156
references: J Cancer Res Clin Oncol. 2008 May;134(5):597-607
references: 17932689
references: Drug Metab Dispos. 2008 Apr;36(4):695-701
references: 18216274
references: J Pharmacol Exp Ther. 2004 Aug;310(2):703-9
references: 15056727
references: J Pharmacol Exp Ther. 2003 Mar;304(3):1085-92
references: 12604685
references: J Pharmacol Exp Ther. 2009 Sep;330(3):956-63
references: 19491323
references: Pharm Res. 1995 Jan;12(1):124-8
references: 7724473
references: J Pharmacol Exp Ther. 2011 Jan;336(1):223-33
references: 20952483
references: Clin Cancer Res. 2003 Jul;9(7):2849-55
references: 12855665
references: Mol Cell Biochem. 2008 May;312(1-2):71-80
references: 18259841
references: J Pharmacol Exp Ther. 2010 Jul;334(1):147-55
references: 20421331
references: Mol Cancer Ther. 2010 Feb;9(2):319-26
references: 20103600
references: J Med Chem. 2009 Oct 8;52(19):6073-82
references: 19711894
references: Cancer Res. 1999 Sep 1;59(17):4237-41
references: 10485464
references: J Pharmacokinet Biopharm. 1988 Jun;16(3):303-9
references: 3221328
references: J Pharmacol Exp Ther. 2013 Mar;344(3):655-64
references: 23249624
references: Bioorg Med Chem. 2011 Jan 15;19(2):861-70
references: 21185730
references: Cancer Chemother Pharmacol. 2000;45(3):207-12
references: 10663638
references: Int J Cancer. 2012 Jan 1;130(1):223-33
references: 21351087
references: J Pharmacol Exp Ther. 2012 Jul;342(1):33-40
references: 22454535
references: Drug Metab Dispos. 2009 Feb;37(2):439-42
references: 19056914
references: J Pharmacol Exp Ther. 2010 Jun;333(3):788-96
references: 20304939
references: Drug Metab Dispos. 2012 Jun;40(6):1164-9
references: 22401960
references: Drug Metab Dispos. 2012 Aug;40(8):1612-9
references: 22611067
references: Mol Imaging Biol. 2011 Feb;13(1):152-60
references: 20379788
references: J Neurooncol. 2012 Jul;108(3):499-506
references: 22407177
references: Cancer Res. 2005 Apr 1;65(7):2577-82
references: 15805252
references: Expert Rev Mol Med. 2011 May 13;13:e17
references: 21676290
references: J Neurochem. 2007 Sep;102(6):1749-1757
references: 17696988
references: Mol Interv. 2010 Oct;10(5):293-304
references: 21045243
references: Mol Pharm. 2012 Mar 5;9(3):678-84
references: 22335402
references: Clin Cancer Res. 2009 Apr 1;15(7):2344-51
references: 19276246